Table 2.

Mortality rates by treatment arm during randomised treatment and extended follow-up

Outcome	Continued thienopyridine (n = 5862), n (%)	Placebo (n = 5786), n (%)	HR (95% CI)	Log-rank P-value
12–30 months (randomized period)
Death	106 (1.9)	84 (1.5)	1.31 (0.97, 1.75)	0.07
Cardiovascular	54 (1.0)	57 (1.0)	1.01 (0.69, 1.47)	0.97
Cardiac	49 (0.9)	52 (0.9)	1.01 (0.68, 1.50)	0.97
Vascular	5 (0.1)	5 (0.1)	0.99 (0.29, 3.40)	0.98
Non-cardiovascular	52 (0.9)	27 (0.5)	1.94 (1.20, 3.15)	0.01
30–33 months (aspirin alone period)
Death	19 (0.4)	13 (0.3)	1.38 (0.67,2.81)	0.38
Cardiovascular	13 (0.3)	5 (0.1)	2.39 (0.84,6.77)	0.09
Cardiac	10 (0.2)	3 (0.1)	2.98 (0.81,10.99)	0.09
Vascular	3 (0.1)	2 (0.1)	1.50 (0.25,9.00)	0.65
Non-cardiovascular	6 (0.1)	8 (0.2)	0.74 (0.26,2.14)	0.58
12–33 months (combined randomized and aspirin alone periods)
Death	125 (2.2)	97 (1.8)	1.32 (1.00,1.73)	0.05
Cardiovascular	67 (1.2)	62 (1.1)	1.12 (0.79,1.60)	0.51
Cardiac	59 (1.1)	55 (1.0)	1.12 (0.77,1.64)	0.54
Vascular	8 (0.1)	7 (0.1)	1.13 (0.41,3.12)	0.81
Non-cardiovascular	58 (1.0)	35 (0.7)	1.65 (1.07,2.54)	0.02

Event rates are expressed as Kaplan–Meier estimates.